Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27117987 | 1.00 | KDM4E (0.45) | KDM4ECA1CA2CA4ALDH1A1 | |
| SCHEMBL21227367 | 1.00 | KDM4E (0.45) | KDM4ECA1CA2CA4ALDH1A1 | |
| SCHEMBL16229734 | 1.00 | KDM4E (0.45) | KDM4ECA1CA2CA4ALDH1A1 | |
| SCHEMBL25741004 | 1.00 | KDM4E (0.45) | KDM4ECA1CA2CA4ALDH1A1 | |
| SCHEMBL24930063 | 0.95 | — | — | |
| SCHEMBL10327054 | 0.95 | — | — | |
| SCHEMBL21227402 | 0.95 | — | — | |
| SCHEMBL21628350 | 0.82 | CA1 (0.34) | KDM4ECA1CA2CA4 | |
| SCHEMBL13745541 | 0.81 | CA1 (0.50) | KDM4ECA1CA2CA4ALDH1A1 | |
| SCHEMBL19055336 | 0.78 | ALDH1A1 (0.38) | KDM4ECA1CA2CA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9057951-B2 | Chemically amplified photoresist composition and process for its use | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2015-06-16 | — | — | US | claimed |
| WO-2011023497-A1 | CHEMICALLY AMPLIFIED PHOTORESIST COMPOSITION AND PROCESS FOR ITS USE | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-03-03 | — | — | WO | claimed |
| US-20240239934-A1 | FUMARIC ACID DIESTER RESIN, FILM AND POLARIZING PLATE | TOSOH CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239934-A1 | FUMARIC ACID DIESTER RESIN, FILM AND POLARIZING PLATE | TOSOH CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| WO-2024044486-A1 | JAK2 INHIBITOR COMPOUNDS | AJAX THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11874434-B2 | Ophthalmic devices comprising photochromic materials with reactive substituents | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-10364237-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-07-26 | — | — | US | disclosed |
| WO-2018106606-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180148396-A1 | Methods of Making Fused Ring Compounds | TRANSITIONS OPTICAL, INC. | 2018-05-31 | — | — | US | disclosed |
| WO-2009125809-A1 | PIPERIDINE DERIVATIVES | 第一三共株式会社 (JP) | 2009-10-15 | — | — | WO | disclosed |
| US-7556750-B2 | Photochromic materials with reactive substituents | TRANSITIONS OPTICAL, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090054472-A1 | Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof | TEIJIN PHARMA LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090032782-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-7481955-B2 | Photochromic materials comprising metallocenyl groups | TRANSITIONS OPTICAL, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080225400-A1 | PHOTOCHROMIC MATERIALS AND PHOTOCHROMIC COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080103301-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20070278460-A1 | Photochromic materials comprising metallocenyl groups | TRANSITIONS OPTICAL LIMITED (IE) | 2007-12-06 | — | — | US | disclosed |
| US-20070278461-A1 | PHOTOCHROMIC MATERIALS COMPRISING HALOALKYL GROUPS | TRANSITIONS OPTICAL, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054472-A1 | Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | KDM4E 1843/4885CA1 2793/4885CA2 840/4885 |
| US-20080103301-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | PNPO, FLAD1, CRY2 | KDM4E 774/4885CA1 4401/4885CA2 3887/4885 |
| US-20090032782-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | INTS6, INCENP, PCNA | KDM4E 2421/4885CA1 3324/4885CA2 3524/4885 |
| US-10364237-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | KDM4E 2966/4885CA1 2353/4885CA2 2714/4885 |
| US-20180148396-A1 | Methods of Making Fused Ring Compounds | CYP2B6, CYP2A6, INTS6 | KDM4E 3567/4885CA1 2879/4885CA2 2586/4885 |
| US-20070278461-A1 | PHOTOCHROMIC MATERIALS COMPRISING HALOALKYL GROUPS | TELO2, EYA3, CRY2 | KDM4E 2611/4885CA1 1026/4885CA2 590/4885 |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | KDM4E 2966/4885CA1 2353/4885CA2 2714/4885 |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | KDM4E 3127/4885CA1 2128/4885CA2 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.